Long noncoding RNA LOC646029 functions as a ceRNA to suppress ovarian cancer progression through the miR-627-3p/SPRED1 axis.
10.1007/s11684-023-1004-z
- Author:
Pengfei ZHAO
1
;
Yating WANG
2
;
Xiao YU
1
;
Yabing NAN
1
;
Shi LIU
1
;
Bin LI
2
;
Zhumei CUI
3
;
Zhihua LIU
4
Author Information
1. State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
2. Department of Gynecological Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
3. Department of Obstetrics and Gynecology, The Affiliated Hospital of Qingdao University, Qingdao, 266000, China. cuizhumei1966@qdu.edu.cn.
4. State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. liuzh@cicams.ac.cn.
- Publication Type:Journal Article
- Keywords:
SPRED1;
lncRNA LOC646029;
metastasis;
microRNA 627-3p;
ovarian cancer
- MeSH:
Humans;
Female;
MicroRNAs/metabolism*;
RNA, Long Noncoding/metabolism*;
RNA, Competitive Endogenous;
Cell Line, Tumor;
Ovarian Neoplasms/genetics*;
Cell Proliferation/genetics*;
Gene Expression Regulation, Neoplastic;
Cell Movement/genetics*;
Adaptor Proteins, Signal Transducing/metabolism*
- From:
Frontiers of Medicine
2023;17(5):924-938
- CountryChina
- Language:English
-
Abstract:
Long noncoding RNAs (lncRNAs) play a crucial regulatory role in the development and progression of multiple cancers. However, the potential mechanism by which lncRNAs affect the recurrence and metastasis of ovarian cancer remains unclear. In the current study, the lncRNA LOC646029 was markedly downregulated in metastatic ovarian tumors compared with primary tumors. Gain- and loss-of-function assays demonstrated that LOC646029 inhibits the proliferation, invasiveness, and metastasis of ovarian cancer cells in vivo and in vitro. Moreover, the downregulation of LOC646029 in metastatic ovarian tumors was strongly correlated with poor prognosis. Mechanistically, LOC646029 served as a miR-627-3p sponge to promote the expression of Sprouty-related EVH1 domain-containing protein 1, which is necessary for suppressing tumor metastasis and inhibiting KRAS signaling. Collectively, our results demonstrated that LOC646029 is involved in the progression and metastasis of ovarian cancer, which may be a potential prognostic biomarker.
